The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Evaluation of chemotherapy with cisplatin plus gemcitabine after failure of gemcitabine alone for unresectable or recurrent biliary tract cancer.
Ryo Kameda
No relevant relationships to disclose
Tomoko Ando
No relevant relationships to disclose
Satoshi Kobayashi
No relevant relationships to disclose
Makoto Ueno
No relevant relationships to disclose
Shinichi Ohkawa
No relevant relationships to disclose